Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes

摘要: Ocular herpes simplex virus (HSV) infection remains a major cause of corneal blindness. Several topical and oral antiviral medications have been used to treat herpetic keratitis. Advances in ophthalmic antivirals made over the past several decades. The first that were discovered cytotoxic, while developed more recently, such as acyclovir ganciclovir, exceeded these drugs both efficacy tolerability. Commercially available outside US since 1996, ganciclovir gel, 0.15% (GCV 0.15%, European tradename: Virgan((R))) is sold than 30 countries has become standard care treating acute GCV studied animal models ocular herpes, healthy volunteers, clinical studies. It found be safe effective at superficial Previous preclinical studies shown activity against common adenovirus strains one recent study demonstrated effect adenoviral conjunctivitis. This review intended provide comprehensive overview including brief summary etiology treatments for HSV, an explanation mechanism action, compendium studies, introduction into new areas interest involving this drug.